Clinical View of Carcinoma

Authors

  • Gyanendra kumar Gupta Professor & Head, Department of Physiology, R.K Institute of Ayurvedic Medical Science Dewrania, Bareilly, Uttar Pradesh, India
  • Gagan Devi Assistant Professor, Department of Anatomy, R.K. Institute of Ayurvedic Medical Science, Dewrania, Bareilly, Uttar Pradesh, India

Keywords:

Cancer, Disease, Physiology, Tumor and Pathological state

Abstract

Cancer describes a large group of diseases, which have one common thing i.e., cells that are growing out of control. Cells that make up all parts of our body go through a predictable life cycles-old cells die, and new cells arrives to take their place, this occurs in physiology of our body. This process goes away, and cells begin to multiply out of control. The end result is the mass of cells called a Tumour i.e. a Pathological state.

References

Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976 Feb 19; 294(8): 405-10.

Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958 Jul 10; 259(2): 66-74.

Jaffe N, Link MP, Cohen D, Traggis D, Frei E 3rd, Watts H, Beardsley GP, Abelson HT. High-dose methotrexate in osteogenic sarcoma. Natl Cancer Inst Monogr 1981 Apr; (56): 201-6.

Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002 Aug 30; 277(35): 32214-9.

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 Mar 13; 348(11): 994-1004.

Abeloff: Clinical Oncology, 3rd ed. Churchill Livingston, 2004. Pp 408-413.

Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A and McLennan MT. Nitrogen mustard therapy. Use of methyl-bis(betachloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. J Am Med Assoc. 1946 Sep 21; 132(2): 126-32.

Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg. 1963 May; 105(5), 4-8

Gilman A. The biological actions and therapeutic applications of the Bchloroethyl amines and sulfides. Science 1946 Apr 5; 103(2675):409-36.

Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic antagonist, 4aminopteroylglutamic acid (aminopterin). N Engl J Med 1948 Jun 3; 238(23):787-93.

Downloads

Published

2022-01-05

Issue

Vol. 10 No. 3 (2021)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.